News

Scenesse improves life quality in EPP adults: Real-world study

Short- and long-term treatment with Scenesse (afamelanotide) improves life quality in adults with erythropoietic protoporphyria (EPP), according to the largest real-world study of its kind. The therapy’s safety profile among those over 70 was consistent with that of the overall patient population, with nausea, cold-like symptoms, headache, and fatigue…

Boy’s congenital erythropoietic porphyria diagnosis takes years

A boy’s long medical odyssey, which eventually led to a diagnosis of congenital erythropoietic porphyria (CEP) but left the child with long-term disabilities, demonstrates the need for timely recognition of this rare form of porphyria, per a report from India. “This case report illustrates the complex and challenging journey…

Teen girl with encephalopathy diagnosed with AIP: Case study

A 15-year-old girl who developed seizures and changes in her mental health status was diagnosed with acute intermittent porphyria (AIP) associated with encephalopathy, or changes in brain function, a U.S. study reports. The clinicians noted her initial presentation was confusing with apparently unrelated symptoms. However, the girl did show…

Delayed diagnosis, high healthcare costs in porphyrias EPP, XLP: Study

Multiple testing and specialist appointments are often needed for diagnosing erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and both conditions are frequently associated with significant healthcare costs. That’s according to a real-world study that analyzed the medical records of EPP and XLP patients in the U.S. The patients waited about…